Abstract
Galectins,β-galactoside binding proteins, function in several physiological and pathological processes. The further evaluation of these processes as well as possible applications of galectins in diagnosis and therapy has raised high scientific interest. Therefore, easy and reliable test systems are necessary. Here we present the simple and cost-efficient production of recombinant human galectins as fusion proteins with SNAP-tag and fluorescent proteins. These constructs show binding specificities and oligomerisation properties generally comparable to recombinant galectins. Their direct fluorescence signal was utilised by ELISA-type assay and flow cytometry analysis with human and ovine mesenchymal stem cells (MSC). Flow cytometry demonstrated glycan mediated binding of His6-SNAP-YFP-Gal- 3 to both MSC types, which was specifically inhibited by lactose. Moreover, directed immobilisation by SNAP-tag technology onto benzylguanine- activated sepharose was utilised to prepare galectin affinity columns for glycoprotein analysis and purification. The SNAPtag directed coupling yielded up to three-fold higher binding capacities for the glycoprotein standard asialofetuin compared to nondirected coupled galectin suggesting improved functionality following directed coupling.
Keywords: Galectin-1, galectin-3, SNAP-tag, fusion protein, fluorescent protein, mesenchymal stem cells.
Current Pharmaceutical Design
Title:Fluorescent SNAP-Tag Galectin Fusion Proteins as Novel Tools in Glycobiology
Volume: 19 Issue: 30
Author(s): Christiane E. Kupper, Sophia Böcker, Hulong Liu, Carina Adamzyk, Julia van de Kamp, Tobias Recker, Bernd Lethaus, Willi Jahnen-Dechent, Sabine Neuss, Gerhard Muller-Newen and Lothar Elling
Affiliation:
Keywords: Galectin-1, galectin-3, SNAP-tag, fusion protein, fluorescent protein, mesenchymal stem cells.
Abstract: Galectins,β-galactoside binding proteins, function in several physiological and pathological processes. The further evaluation of these processes as well as possible applications of galectins in diagnosis and therapy has raised high scientific interest. Therefore, easy and reliable test systems are necessary. Here we present the simple and cost-efficient production of recombinant human galectins as fusion proteins with SNAP-tag and fluorescent proteins. These constructs show binding specificities and oligomerisation properties generally comparable to recombinant galectins. Their direct fluorescence signal was utilised by ELISA-type assay and flow cytometry analysis with human and ovine mesenchymal stem cells (MSC). Flow cytometry demonstrated glycan mediated binding of His6-SNAP-YFP-Gal- 3 to both MSC types, which was specifically inhibited by lactose. Moreover, directed immobilisation by SNAP-tag technology onto benzylguanine- activated sepharose was utilised to prepare galectin affinity columns for glycoprotein analysis and purification. The SNAPtag directed coupling yielded up to three-fold higher binding capacities for the glycoprotein standard asialofetuin compared to nondirected coupled galectin suggesting improved functionality following directed coupling.
Export Options
About this article
Cite this article as:
Kupper E. Christiane, Böcker Sophia, Liu Hulong, Adamzyk Carina, Kamp van de Julia, Recker Tobias, Lethaus Bernd, Jahnen-Dechent Willi, Neuss Sabine, Muller-Newen Gerhard and Elling Lothar, Fluorescent SNAP-Tag Galectin Fusion Proteins as Novel Tools in Glycobiology, Current Pharmaceutical Design 2013; 19 (30) . https://dx.doi.org/10.2174/1381612811319300017
DOI https://dx.doi.org/10.2174/1381612811319300017 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease
Current Alzheimer Research The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations
Current Drug Delivery HIV-1 IN Inhibitors: 2010 Update and Perspectives
Current Topics in Medicinal Chemistry Relevance of the Neuropeptide Y System in the Biology of Cancer Progression
Current Topics in Medicinal Chemistry Current Management of Neonatal Liver Tumors
Current Pediatric Reviews Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Current Molecular Pharmacology Essential Role of Gli Proteins in Glioblastoma Multiforme
Current Protein & Peptide Science Therapeutic Targets for Metastatic Prostate Cancer
Current Drug Targets Synthetic and Natural Immunomodulators Acting as Interferon Inducers
Current Pharmaceutical Design Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets Parthenogenetic Cell Lines: An Unstable Equilibrium Between Pluripotency and Malignant Transformation
Current Pharmaceutical Biotechnology Molecular Pathology of Sarcomas
Reviews on Recent Clinical Trials Bcl-2 Targeted-Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Smart Drug-Delivery Systems for Cancer Nanotherapy
Current Drug Targets The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry Magnetically Responsive Paclitaxel-Loaded Biodegradable Nanoparticles for Treatment of Vascular Disease: Preparation, Characterization and In Vitro Evaluation of Anti-Proliferative Potential
Current Drug Delivery Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets